A trial testing four potential Ebola vaccines has been halted after public health officials in the Democratic Republic of the Congo determined that two of the four vaccines were more effective at preventing mortality in patients infected with the Ebola virus. A new extension trial will be launched for Regeneron Pharmaceuticals' REGN-EB3, created using antibodies generated in mice, and for the National Institute of Allergy and Infectious Diseases-developed mAb114, which was created using antibodies derived from a patient who survived Ebola and is licensed to Ridgeback Biotherapeutics.
2 investigational Ebola vaccines show potential for reducing mortality
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.